The tar­get is the sys­tem: Con­den­sates biotech as­pires to ‘rewrite the rule­book’ on drug dis­cov­ery

An­oth­er biotech has burst in­to the buzzy but still bud­ding field of bio­mol­e­c­u­lar con­den­sates with $50 mil­lion in Se­ries A fund­ing.

Tran­si­tion Bio, based in both Cam­bridge, UK, and Cam­bridge, MA, is look­ing to bring con­den­sate drug dis­cov­ery, a field that orig­i­nat­ed in neu­ro­science, to can­cer. Co-found­ed by two bio­physics pro­fes­sors — David Weitz of Har­vard and Tuo­mas Knowles of the Uni­ver­si­ty of Cam­bridge — the 18-month-old biotech is build­ing a ma­chine learn­ing plat­form that maps out con­den­sates in what Knowles de­scribed as a “phase di­a­gram.”

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER